Chemotherapy with or without hormone drug for premenopausal TNBC
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether adding a hormone-blocking drug (GnRH agonist) to standard chemotherapy before surgery helps premenopausal women with triple-negative breast cancer. It aims to improve treatment outcomes by targeting hormones that may fuel tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older and have not gone through menopause.
- You have been diagnosed with triple-negative or hormone receptor-low/HER2-negative breast cancer that has not spread beyond the breast and nearby lymph nodes.
- You have not received any prior treatment for breast cancer (such as chemotherapy, radiation, or surgery).
- You are willing to have a small needle biopsy of the tumor for research and to undergo breast cancer surgery as part of your treatment plan.
- You are generally in good health, with adequate blood count, liver, and kidney function, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining immunotherapy, hormone therapy, and an AKT-blocking drug can control ER-positive advanced breast cancer in women whose cancer is resistant to hormone treatment. It may help shrink tumors and slow disease by targeting several pathways at once.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
This study tests whether a new approach using a genetic test can guide treatment for low-risk triple-negative breast cancer. It aims to help patients avoid unnecessary chemotherapy while keeping the cancer from coming back.
This Phase 3 trial compares hormone-based treatment versus chemotherapy given before surgery in people who are premenopausal and have hormone-receptor positive, HER2-negative breast cancer. It looks to see which approach works better to control the cancer before the breast operation.
This trial tests a new approach: combining hormone therapy with chemotherapy before surgery for early-stage breast cancer. It may help shrink the tumor and improve chances of successful treatment.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.